Johnson & Johnson Beat Q1 Earnings, Boosts 2021 Guidance; Reports $100M In COVID-19 Vaccine Sales

 


  • Johnson & Johnson JNJ has posted stronger-than-expected Q1 earnings and boosted its full-year earnings forecast as medical device and pharmaceutical sales recorded post-pandemic gains.

  • J&J’s financial results come as the company’s COVID-19 vaccine has been put on pause in the U.S. after six women developed a rare blood clotting disorder that left one dead and one in critical condition.

  • White House chief medical advisor Dr. Anthony Fauci believes that JNJ shots are likely to be resumed with a warning this week.

  • Adjusted earnings of $2.59 per share were up 12.6% from a year ago, well ahead of the consensus forecast of $2.34 per share.

  • Consolidated revenues increased 7.9% to $22.3 billion, again beating analysts’ estimates of a $22 billion tally.

  • “Johnson & Johnson delivered a strong first-quarter performance led by the above-market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said CEO Alex Gorsky.

  • Consumer Health sales declined 2.3% Y/Y to $3.5 billion, primarily driven by a 13% drop in sales from over-the-counter products. 

  • Pharmaceutical sales were up 9.6% to $12.2 billion driven by Darzalex, Stelara, Erleada, Tremfya, paliperidone palmitate, and Imbruvica.

  • Medical Devices segment sales grew 10.9% to $6.6 billion, reflecting the benefit of market recovery from COVID-19 impacts. 

  • The company also tightened the range of its 2021 adjusted earnings forecast to $9.42 to $9.57 per share while projecting sales in the range of $90.6 billion and $91.6 billion, representing an increase of 9.3% at the midpoint.

  • The company reported $100 million in sales from the COVID-19 vaccine that received emergency use nod in late February.

  • JNJ increased the quarterly dividend by 5%, from $1.01 per share to $1.06 per share, resulting in a dividend on an annual basis is $4.24 per share compared to the previous rate of $4.04 per share. 

  • Separately, Johnson & Johnson has applied to India’s drug regulator seeking permission to conduct a Phase-3 trial of its single-dose COVID-19 vaccine as well as import license, sources said.

  • Price Action: JNJ shares are down 0.2% at $162.42 in premarket on the last check Tuesday.



  •  
  •  

 

Related content: Benzinga's Full Guidance Calendar

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceDividendsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!